Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 127 results for epilepsy

  1. Bipolar disorder: assessment and management (CG185)

    This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.

    Clinical guideline
    Last updated
    2 September 2025
    View recommendations

    Sections for CG185

  2. MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (IPG671)

    We have moved interventional procedures guidance 671 to become HealthTech guidance 541. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

    HealthTech guidance
    Published
    7 May 2025
    View recommendations

    Sections for HTG748

  4. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Withdrawn advice

  5. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

    Medtech innovation briefing
    Last updated
    9 June 2023

  6. Antiseizure medication for repeated or cluster seizures: What antiseizure medications (monotherapy or add-on) are effective in the treatment of repeated or cluster seizures?

    therapies. Source guidance details Comes from guidance Epilepsies in children, young people and adults Number NG217 Date

    Research recommendation
    Published
    11 May 2022

  7. Risk prediction tool for second seizure: Development of a risk prediction tool for second seizures in people with a single seizure, and an external validation of a risk prediction tool to detect the probability of a second seizure in people with a single seizure at baseline.

    seizure. Source guidance details Comes from guidance Epilepsies in children, young people and adults Number NG217 Date

    Research recommendation
    Published
    11 May 2022

  8. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST26

  9. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Infantile spasms: Does treatment response relate to cause in infantile spasms? Does early treatment success in seizure control and resolution of the hypsarrhythmic EEG influence the long-term developmental and cognitive outcomes more than the underlying cause of the spasms?

    pharmaco-resistance. Source guidance details Comes from guidance Epilepsies: diagnosis and management Number CG137 Date issued

    Research recommendation
    Published
    13 August 2021

  11. Treatment of convulsive status epilepticus (that is, not just refractory): What is the most effective and safest AED to treat: established (usually lasting longer than 30 minutes) convulsive status epilepticus refractory convulsive status epilepticus?

    care. Source guidance details Comes from guidance Epilepsies: diagnosis and management Number CG137 Date issued

    Research recommendation
    Published
    13 August 2021

  12. Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)

    This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.

    NICE guideline
    Published
    6 March 2024
    View recommendations

    Sections for NG239

  13. Learning disability: behaviour that challenges (QS101)

    This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.

    Quality standard
    Last updated
    24 July 2019
    View quality statements

    Sections for QS101

  14. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care (CG20)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guideline

  15. Epilepsies: diagnosis and management (CG137)

    This guidance has been updated and replaced by NICE guideline NG217.

    Withdrawn guideline